Table 2 |
|||||||||
|
Key clinical characteristics of the patients related to their serological response to HPV16 antigens |
|||||||||
|
Variables |
Anti-E and -L |
Anti-E4-E6 and E7 |
Anti L1 and -L2 |
||||||
|
|
|
|
|
||||||
|
+ |
- |
Sign. |
+ |
- |
Sign. |
+ |
- |
Sign. |
|
|
|
|||||||||
|
HPV DNA (%): |
|||||||||
|
Positive 76 |
89.5 |
10.5 |
OR = 2.8 (0.8–9.9) |
71.1 |
28.9 |
OR = 1.3 (0.4–3.7) |
71.1 |
28.9 |
OR = 1.6 (0.6–4.6) |
|
p = 0.136 |
p = 0.604 |
p = 0.350 |
|||||||
|
Negative 20 |
75.0 |
25.0 |
65.0 |
35.0 |
60.0 |
40.0 |
|||
|
HR-HPV (%) |
|||||||||
|
Positive 66 |
87.9 |
12.1 |
OR = 1.4 (0.4–4.8) |
68.2 |
31.8 |
OR = 0.8 (0.3–2.0) |
69.7 |
30.3 |
OR = 1.1 (0.5–2.9) |
|
p = 0.536 |
p = 0.608 |
p = 0.767 |
|||||||
|
Negative 30 |
83.3 |
16.7 |
73.3 |
26.7 |
66.7 |
33.3 |
|||
|
LR-HPV (%): |
|||||||||
|
Positive 10 |
100 |
0.0 |
OR = NC |
90.0 |
10.0 |
OR = 4.3 (0.5–30.0) |
80.0 |
20.0 |
OR = 1.9 (0.4–9.7): |
|
p = 0.348 |
p = 0.273 |
p = 0.720 |
|||||||
|
Negative 86 |
84.9 |
15.1 |
67.4 |
32.6 |
67.4 |
32.6 |
|||
|
Previous: |
|||||||||
|
HPV (%): |
|||||||||
|
Yes 19 |
94.7 |
5.3 |
OR = 2.8 (0.3–23.9); |
89.5 |
10.5 |
OR = 4.8 (1.1–22.8) |
73.7 |
26.3 |
OR = 0.9 (0.3–3.1); |
|
p = 0.445 |
p = 0.046 |
p = 0.961 |
|||||||
|
No 66 |
86.4 |
13.6 |
63.6 |
36.4 |
74.2 |
25.8 |
|||
|
HIV-Status (%): |
|||||||||
|
Negative 84 |
89.3 |
10.7 |
OR = 4.2(1.1–16.5) |
71.4 |
28.6 |
OR = 1.8 (0.5–6.2) |
72.6 |
27.4 |
OR = 3.7 (1.1–12.9) |
|
p = 0.032 |
p = 0.355 |
p = 0.030 |
|||||||
|
Positive 12 |
66.7 |
33.3 |
58.3 |
41.7 |
41.7 |
58.3 |
|||
|
Smokers 9 |
66.6 |
33.3 |
55.6 |
44.4 |
33.3 |
66.7 |
|||
|
Previous: |
|||||||||
|
PAP (%): |
|||||||||
|
Never 10 |
90.0 |
10.0 |
p = 0.793 |
70.0 |
30.0 |
p = 0.111 |
80.0 |
20.0 |
p = 0.445 |
|
Irregular 26 |
92.3 |
7.7 |
84.6 |
15.4 |
61.5 |
38.5 |
|||
|
Regular (1–3 yrs) 49 |
85.7 |
14.3 |
61.2 |
38.8 |
75.5 |
24.5 |
|||
|
Referral |
|||||||||
|
PAP (%): |
|||||||||
|
ASC-US 7 |
100 |
0.0 |
p = 0.431 |
85.7 |
14.3 |
p = 0.623 |
100 |
0.0 |
p = 0.094 |
|
LSIL 48 |
91.7 |
8.3 |
64.6 |
35.4 |
75.0 |
25.0 |
p = 0.031* |
||
|
HSIL 16 |
81.3 |
18.7 |
68.8 |
31.2 |
56.3 |
43.7 |
|||
|
Biopsy |
|||||||||
|
Result (%): |
|||||||||
|
Normal 1 |
100 |
0.0 |
0.0 |
100 |
100 |
0.0 |
|||
|
HPV-NCIN 9 |
100 |
0.0 |
p = 0.262 |
66.7 |
33.3 |
p = 0.526 |
77.8 |
22.2 |
p = 0.564 |
|
CIN1 11 |
90.9 |
9.1 |
54.5 |
45.5 |
63.6 |
36.4 |
|||
|
CIN2 14 |
92.9 |
7.1 |
71.4 |
28.6 |
85.7 |
14.3 |
|||
|
CIN3 15 |
93.3 |
6.7 |
73.3 |
16.7 |
73.3 |
26.7 |
|||
|
SCC 2 |
50.0 |
50.0 |
50.0 |
50.0 |
50.0 |
50.0 |
|||
|
Genital |
|||||||||
|
Warts (%): |
|||||||||
|
Yes 20 |
95.0 |
5.0 |
OR = 3.3(0.4–27.7) |
80.0 |
20.0 |
OR = 2.1 (0.6–7.0) |
75.0 |
25.0 |
OR = 1.1 (0.4–3.7) |
|
p = 0.437 |
p = 0.275 |
p = 0.801 |
|||||||
|
No 61 |
85.2 |
14.8 |
65.6 |
34.4 |
72.1 |
27.9 |
|||
|
Colposcopy (%): |
|||||||||
|
Normal 2 |
100 |
0.0 |
100 |
0.0 |
0.0 |
100 |
|||
|
Low-grade 27 |
96.3 |
3.74 |
p = 0.177 |
63.0 |
37.0 |
p = 0.668 |
85.2 |
14.8 |
p = 0.015 |
|
High-grade 28 |
77.8 |
22.2 |
72.2 |
27.8 |
61.1 |
28.9 |
|||
|
|
|||||||||
|
NC, non-computable; 1Contraception used until past; 2Contraception in current use; *For linear trend; HPV-NCIN, HPV infection without CIN.... |
|||||||||
|
Giorgi et al. Infectious Agents and Cancer 2008 3:9 doi:10.1186/1750-9378-3-9 |
|||||||||